Jilin Jidong: Net profit in the first half of the year was 430 million, down by 2.92% year-on-year

In the first half of the year, it achieved an operating income of 660,602,100 yuan, an increase of 11,400,200 yuan over the same period of last year, an increase of 20.67%; total profit of 447,769,900 yuan, a decrease of 10,271,200 yuan over the same period of last year, a decrease of 2.25%; to achieve attributable to shareholders of listed companies The net profit was RMB 430.1063 million, a decrease of RMB 12.9244 million or 2.92%, and the decrease in the total profit and the net profit attributable to the shareholders of the listed companies was mainly due to the decrease in investment income as a result of the decrease in the proportion of the company’s shareholding in GF Securities.

During the reporting period, the company mainly did the following:

(1) Accelerate the pace of technological transformation: The State "Standards for the Quality Control of Pharmaceutical Production (Revised in 2010)" was formally implemented in 2011. The Group Company requires subordinate companies to seize the opportunity to speed up the transformation according to the new GMP standard and complete the 2010 version of GMP certification as soon as possible. jobs. Yanbian Pharmaceutical became the first Chinese company in the country, and Jilin Province was the first pharmaceutical company to pass the 2010 GMP on-site inspection. After Yanji Pharmaceutical passed the GMP on-site certification examination of the freeze-dried powder injection and small-volume injections in 2010, Jilin Aodong Herbal Pieces In the report period, the company’s joint-stock company obtained a license for the production of pharmaceuticals and passed the on-site inspection of the 2010 version of GMP. At present, the company has officially started production.

Jilin Jidong Qiannan Pharmaceutical Co., Ltd. carried out an off-site transformation, the basic project had been completed, and the installation and commissioning of equipment was being carried out according to plan, and the 2010 version of the GMP certification work was being completed. Other pharmaceutical subsidiaries also combine their actual certification plans. With the company's sufficient financial support, the company continuously increased its investment in the pharmaceutical industry to upgrade the company’s files and greatly enhance its core competitiveness.

(2) Establish a quality control system: Through the 2010 version of GMP certification and learning, the company has consistently adhered to the development philosophy of “people-oriented, honest management” in accordance with the requirements of the internal control specification operating guidelines and firmly established the idea that “quality is the life of an enterprise”. Concepts: Three levels of quality control systems have been established: Quality Authenticators, Quality Assurance Departments, and Quality Control Departments. They are controlled at each level and controlled step by step to form a complete quality supervision network system. From material procurement, pharmaceutical production, product sales and after-sales service The entire process of the service carries out quality control to ensure that unqualified raw materials are not put into production, unqualified intermediate products do not flow into the next process, and unqualified finished products do not leave the factory, effectively guaranteeing product quality and safety.

In spite of the "Chromium exceeding standard capsule" incident during the reporting period, each pharmaceutical subsidiary passed self-inspection, mutual inspection, and dozens of spot inspections by the local, provincial and provincial food and drug administration bureaus to prove that the company purchased, produced, used, and invented gelatin. Hollow capsules and the drug products sold, in production, and in capsules all meet the quality standards of the “Chinese Pharmacopoeia” (2010 edition II), reflecting the effectiveness of the company’s pharmaceutical quality control system and the reliability of its product quality. The consumer's wide acclaim.

(3) Establishing a multi-dimensional marketing model: The company constantly explores and explores suitable marketing models, and initially establishes a sales model that includes a combination of national distributors, package sales, and academic promotion, and sells talent through recruitment and sales. Teams, refinement of assessment goals, etc., established the idea that the market is the dominant, constantly refined the sales management, and effectively improved the company’s sales target. At the same time, the company adopted a multi-level marketing campaign to increase the company’s visibility and product influence, using the strategy of “developing large varieties steadily and small varieties across the development”, and in-depth analysis and research of varieties, combined with theoretical research and unique features. Publicity and other effective work will be carried out to promote the rapid growth of the company's pharmaceutical industry.

(4) Major projects progressed smoothly: In order to better implement the strategy of “longitudinal development and building a pharmaceutical industry chain structure”, the company invested in the construction of standardized medicine packaging plant, capsules, straws and other pharmaceutical packaging materials projects in the industrial park. At present, in order to ensure the maintenance and maintenance of raw and auxiliary materials, Chinese Herbal Pieces Company has built a domestic first-rate constant temperature and humidity raw material library and finished product library, and equipped with a variety of advanced detection equipment, which can effectively guarantee the quality of raw materials; Shunhe Capsule's automatic capsule production line has been officially put into production , Actively expanding external business on the premise of satisfying the company's internal production; The civil construction work of Liyuan Pharmaceutical's off-site reconstruction project was basically completed, and it strived to build a national-level traditional Chinese medicine formula granule base, and related work was also progressing in an orderly manner; The enzyme series products have been trial production. The trial production currently produces 50,000 liters of enzyme stock solution. The investment in the Tadong iron ore infrastructure in 2008 has been completed. The production equipment is currently being commissioned and is expected to be put into production within the year. At present, ELAD bioartificial liver is still waiting for the approval of China National Food and Drug Administration (acceptance number is: 07-2567).